|
1
|
Robert Koch Institut: Krebs in Deutschland
2011/2012. 10th. Berlin: 2015, (In German). http://www.gekid.de/Doc/krebs_in_deutschland_2015.pdf
|
|
2
|
National Cancer Institute. simplewww.cancer.govNIHAccessed. Nov;2015.
|
|
3
|
Badve S, Dabbs DJ, Schnitt SJ, Baehner FL,
Decker T, Eusebi V, Fox SB, Ichihara S, Jacquemier J, Lakhani SR,
et al: Basal-like and triple-negative breast cancers: A critical
review with an emphasis on the implications for pathologists and
oncologists. Mod Pathol. 24:157–167. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Brenton JD, Carey LA, Ahmed AA and Caldas
C: Molecular classification and molecular forecasting of breast
cancer: Ready for clinical application? J Clin Oncol. 23:7350–7360.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dawood S: Triple-negative breast cancer:
Epidemiology and management options. Drugs. 70:2247–2258. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kennecke H, Yerushalmi R, Woods R, Cheang
MC, Voduc D, Speers CH, Nielsen TO and Gelmon K: Metastatic
behavior of breast cancer subtypes. J Clin Oncol. 28:3271–3277.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hugh J, Hanson J, Cheang MC, Nielsen TO,
Perou CM, Dumontet C, Reed J, Krajewska M, Treilleux I, Rupin M, et
al: Breast cancer subtypes and response to docetaxel in
node-positive breast cancer: Use of an immunohistochemical
definition in the BCIRG 001 trial. J Clin Oncol. 27:1168–1176.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mehta RS: Dose-dense and/or metronomic
schedules of specific chemotherapies consolidate the
chemosensitivity of triple-negative breast cancer: A step toward
reversing triple-negative paradox. J Clin Oncol. 26:3286–3288.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liedtke C, Mazouni C, Hess KR, André F,
Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B,
Green M, et al: Response to neoadjuvant therapy and long-term
survival in patients with triple-negative breast cancer. J Clin
Oncol. 26:1275–1281. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
O'Shaughnessy J, Osborne C, Pippen JE,
Yoffe M, Patt D, Rocha C, Koo IC, Sherman BM and Bradley C:
Iniparib plus chemotherapy in metastatic triple-negative breast
cancer. N Engl J Med. 364:205–214. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Linderholm BK, Hellborg H, Johansson U,
Elmberger G, Skoog L, Lehtiö J and Lewensohn R: Significantly
higher levels of vascular endothelial growth factor (VEGF) and
shorter survival times for patients with primary operable
triple-negative breast cancer. Ann Oncol. 20:1639–1646. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Schutz FA, Jardim DL, Je Y and Choueiri
TK: Haematologic toxicities associated with the addition of
bevacizumab in cancer patients. Eur J Cancer. 47:1161–1174. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
von Minckwitz G, Eidtmann H, Rezai M,
Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C,
Kreienberg R, et al: German Breast Group; Arbeitsgemeinschaft
Gynäkologische Onkologie-Breast Study Groups: Neoadjuvant
chemotherapy and bevacizumab for HER2-negative breast cancer. N
Engl J Med. 366:299–309. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Grob TJ, Heilenkötter U, Geist S,
Paluchowski P, Wilke C, Jaenicke F, Quaas A, Wilczak W, Choschzick
M, Sauter G, et al: Rare oncogenic mutations of predictive markers
for targeted therapy in triple-negative breast cancer. Breast
Cancer Res Treat. 134:561–567. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Viale G, Rotmensz N, Maisonneuve P,
Bottiglieri L, Montagna E, Luini A, Veronesi P, Intra M, Torrisi R,
Cardillo A, et al: Invasive ductal carcinoma of the breast with the
‘triple-negative’ phenotype: Prognostic implications of EGFR
immunoreactivity. Breast Cancer Res Treat. 116:317–328. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Baselga J, Stemmer S, Pego A, Chan A,
Goeminne JC, Graas MP, Kennedy J, Gil Ciruelos EM, Zubel A, et al:
Abstract PD01-01: Cetuximab + cisplatin in estrogen
receptor-negative, progesterone receptor-negative, Her2-negative
(triple-negative) metastatic breast cancer: Results of the
randomized phase II BALI-trial. Cancer Res (Thirty-Third Annual
CTRC-AACR San Antonio Breast Cancer Symposium). 70:PD01–01.
2010.
|
|
17
|
Yunokawa M, Koizumi F, Kitamura Y,
Katanasaka Y, Okamoto N, Kodaira M, Yonemori K, Shimizu C, Ando M,
Masutomi K, et al: Efficacy of everolimus, a novel mTOR inhibitor,
against basal-like triple-negative breast cancer cells. Cancer Sci.
103:1665–1671. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Qiu M, Peng Q, Jiang I, Carroll C, Han G,
Rymer I, Lippincott J, Zachwieja J, Gajiwala K, Kraynov E, et al:
Specific inhibition of Notch1 signaling enhances the antitumor
efficacy of chemotherapy in triple negative breast cancer through
reduction of cancer stem cells. Cancer Lett. 328:261–270. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhu H, Bhaijee F, Ishaq N, Pepper DJ,
Backus K, Brown AS, Zhou X and Miele L: Correlation of Notch1, pAKT
and nuclear NF-κB expression in triple negative breast cancer. Am J
Cancer Res. 3:230–239. 2013.PubMed/NCBI
|
|
20
|
Schwab LP, Peacock DL, Majumdar D, Ingels
JF, Jensen LC, Smith KD, Cushing RC and Seagroves TN:
Hypoxia-inducible factor 1α promotes primary tumor growth and
tumor-initiating cell activity in breast cancer. Breast Cancer Res.
14:R62012. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen X, Iliopoulos D, Zhang Q, Tang Q,
Greenblatt MB, Hatziapostolou M, Lim E, Tam WL, Ni M, Chen Y, et
al: XBP1 promotes triple-negative breast cancer by controlling the
HIF1α pathway. Nature. 508:103–107. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lopes LF, Guembarovski RL, Guembarovski
AL, Kishima MO, Campos CZ, Oda JM, Ariza CB, de Oliveira KB,
Borelli SD and Watanabe MA: FOXP3 transcription factor: A candidate
marker for susceptibility and prognosis in triple negative breast
cancer. Biomed Res Int. 2014:3416542014.PubMed/NCBI
|
|
23
|
Takenaka M, Seki N, Toh U, Hattori S,
Kawahara A, Yamaguchi T, Koura K, Takahashi R, Otsuka H, Takahashi
H, et al: FOXP3 expression in tumor cells and tumor-infiltrating
lymphocytes is associated with breast cancer prognosis. Mol Clin
Oncol. 1:625–632. 2013.PubMed/NCBI
|
|
24
|
Kim W, Kim SY, Kim T, Kim M, Bae DJ, Choi
HI, Kim IS and Jho E: ADP-ribosylation factors 1 and 6 regulate
Wnt/β-catenin signaling via control of LRP6 phosphorylation.
Oncogene. 32:3390–3396. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mahamodhossen YA, Liu W and Rong-Rong Z:
Triple-negative breast cancer: New perspectives for novel
therapies. Med Oncol. 30:6532013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yang L, Perez AA, Fujie S, Warden C, Li J,
Wang Y, Yung B, Chen YR, Liu X, Zhang H, et al: Wnt modulates MCL1
to control cell survival in triple negative breast cancer. BMC
Cancer. 14:1242014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Remmele W and Stegner HE: Recommendation
for uniform definition of an immunoreactive score (IRS) for
immunohistochemical estrogen receptor detection (ER-ICA) in breast
cancer tissue. Pathologe. 8:138–140. 1987.PubMed/NCBI
|
|
28
|
Jin Y, Wang H, Liang X, Ma J and Wang Y:
Pathological and prognostic significance of hypoxia-inducible
factor 1α expression in epithelial ovarian cancer: A meta-analysis.
Tumour Biol. 35:8149–8159. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang Y, Liu Y, Ma JX, Li BX and Li YK:
Effect of the Wnt/LRP5/β-catenin signaling pathway on the
pathogenesis of postmenopausal osteoporosis. Zhonghua Fu Chan Ke Za
Zhi. 46:769–772. 2011.(In Chinese). PubMed/NCBI
|
|
30
|
Yin L, Gao Y, Zhang X, Wang J, Ding D,
Zhang Y, Zhang J and Chen H: Niclosamide sensitizes triple-negative
breast cancer cells to ionizing radiation in association with the
inhibition of Wnt/β-catenin signaling. Oncotarget. 7:42126–42138.
2016.PubMed/NCBI
|
|
31
|
Rangel MC, Bertolette D, Castro NP,
Klauzinska M, Cuttitta F and Salomon DS: Developmental signaling
pathways regulating mammary stem cells and contributing to the
etiology of triple-negative breast cancer. Breast Cancer Res Treat.
156:211–226. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cao YW, Wan GX, Sun JP, Cui XB, Hu JM,
Liang WH, Zheng YQ, Li WQ and Li F: Implications of the
Notch1-Snail/Slug-epithelial to mesenchymal transition axis for
lymph node metastasis in infiltrating ductal carcinoma. Kaohsiung J
Med Sci. 31:70–76. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cao YW, Li WQ, Wan GX, Li YX, Du XM, Li YC
and Li F: Correlation and prognostic value of SIRT1 and Notch1
signaling in breast cancer. J Exp Clin Cancer Res. 33:972014.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mohammadi-Yeganeh S, Mansouri A and Paryan
M: Targeting of miR9/NOTCH1 interaction reduces metastatic behavior
in triple-negative breast cancer. Chem Biol Drug Des. 86:1185–1191.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Pamarthy S, Mao L, Katara GK, Fleetwood S,
Kulshreshta A, Gilman-Sachs A and Beaman KD: The V-ATPase a2
isoform controls mammary gland development through Notch and TGF-β
signaling. Cell Death Dis. 7:e24432016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lee KM, Nam K, Oh S, Lim J, Kim RK, Shim
D, Choi JH, Lee SJ, Yu JH, Lee JW, et al: ECM1 regulates tumor
metastasis and CSC-like property through stabilization of
β-catenin. Oncogene. 34:6055–6065. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kumar KJ, Vani MG, Chueh PJ, Mau JL and
Wang SY: Antrodin C inhibits epithelial-to-mesenchymal transition
and metastasis of breast cancer cells via suppression of Smad2/3
and β-catenin signaling pathways. PLoS One. 10:e01171112015.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Li X, Liang W, Liu J, Lin C, Wu S, Song L
and Yuan Z: Transducin (β)-like 1 X-linked receptor 1 promotes
proliferation and tumorigenicity in human breast cancer via
activation of beta-catenin signaling. Breast Cancer Res.
16:4652014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang Y, Bu F, Royer C, Serres S, Larkin
JR, Soto MS, Sibson NR, Salter V, Fritzsche F, Turnquist C, et al:
ASPP2 controls epithelial plasticity and inhibits metastasis
through β-catenin-dependent regulation of ZEB1. Nat Cell Biol.
16:1092–1104. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sehgal P, Kumar N, Kumar Praveen VR, Patil
S, Bhattacharya A, Vijaya Kumar M, Mukherjee G and Kondaiah P:
Regulation of protumorigenic pathways by insulin like growth factor
binding protein2 and its association along with β-catenin in breast
cancer lymph node metastasis. Mol Cancer. 12:632013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Dong Y, Zhang T, Li J, Deng H, Song Y,
Zhai D, Peng Y, Lu X, Liu M, Zhao Y, et al: Oridonin inhibits tumor
growth and metastasis through anti-angiogenesis by blocking the
Notch signaling. PLoS One. 9:e1138302014. View Article : Google Scholar : PubMed/NCBI
|
